Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Notes Payables (2021 - 2022)

Historic Notes Payables for Verrica Pharmaceuticals (VRCA) over the last 2 years, with Q2 2022 value amounting to $42.3 million.

  • Verrica Pharmaceuticals' Notes Payables rose 314.11% to $42.3 million in Q2 2022 from the same period last year, while for Jun 2022 it was $42.3 million, marking a year-over-year increase of 314.11%. This contributed to the annual value of $41.7 million for FY2021, which is N/A changed from last year.
  • Latest data reveals that Verrica Pharmaceuticals reported Notes Payables of $42.3 million as of Q2 2022, which was up 314.11% from $42.0 million recorded in Q1 2022.
  • Over the past 5 years, Verrica Pharmaceuticals' Notes Payables peaked at $42.3 million during Q2 2022, and registered a low of $40.0 million during Q1 2021.